Stay up-to-date on new clinical findings in Oncoderm.
Oncoderm Supplements
In the Nordic European Countries, cancer is the leading cause of death. The last decade has brought revolutionizing cancer treatments including immune checkpoint inhibitors (ICIs). Patients on ICIs have a high risk of developing cutaneous immune-related adverse events. Treating these side effects is of high importance to improve patient’s quality of life (QoL) and continue the anti-cancer treatment.
In the Nordic European Countries, cancer is the leading cause of death. The last decade has brought revolutionizing cancer treatments including immune checkpoint inhibitors (ICIs). Patients on ICIs have a high risk of developing cutaneous immune-related adverse events. Treating these side effects is of high importance to improve patient’s quality of life (QoL) and continue the anti-cancer treatment.
In 2023, nearly 2 million patients will be diagnosed with cancer in the United States and at least 40% will be eligible for treatment with an immune checkpoint inhibitor (ICI).
USCOM Algorithm for the Prevention and Management of Cutaneous Immunotherapy-Related Adverse Events
Background: In 2023, nearly 2 million patients will be diagnosed with cancer in the United States and at least 40% will be eligible for treatment with an immune checkpoint inhibitor (ICI).
In the Nordic European countries in 2020, cancer diagnoses accounted for 175,925 patients. About 50% of cancer patients receive radiation therapy (RT), which may lead to radiation dermatitis (RD). Notably, patients with breast, head, neck, and anal cancers may be prone to developing RD. However, few algorithms exist for the prevention and treatment of RD.
Background: In the Nordic European countries in 2020, cancer diagnoses accounted for 175,925 patients. About 50% of cancer patients receive radiation therapy (RT), which may lead to radiation dermatitis (RD).
In addition to ultraviolet light, skin is regularly exposed to several environmental stressors that can cause damage and premature aging. Particulate matter in the environment, including transition me…
US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm
An increasing number of patients survive or are living with cancer. Anticancer treatments frequently have cutaneous adverse events (cAEs) that may severely impact patients’ quality of life and interrupt anticancer treatment. The US Cutaneous Oncodermatology Management (USCOM) project aims to improve cancer patients’ and survivors’ quality of life by offering tools for preventing and managing cAEs.
Advertisement
Podcasts
Saving Skin, Hair & Nails with Supportive Oncodermatology: A Call to Action for All Those Involved
While the old adage, “more oncology treatments, more skin problems,” becomes more like dogma every day with each new life saving therapy, fear not my friends, help is out there. Joining JDD podcast host Dr. Adam Friedman again, the man, the myth, the supportive oncodermatology legend, Dr. Mario Lacouture shares the latest guidance on managing these hair, skin and nail toxicities that are often considered by the patient even worse then the cancer these drugs treat. Get your support on – your patients will thank you.
This podcast series is supported by La Roche-Posay.
